Skip to main content
Premium Trial:

Request an Annual Quote

Lay-Offs at J&J Pharma Won t Affect Existing Alliances; Not Many Genomic Positions Axed

NEW YORK, March 6 (GenomeWeb News) - Johnson & Johnson's decision to downsize its R&D program, disclosed last month, will not affect existing alliances, including genomic-related partnerships, the company said Friday.


Company spokesperson Ernie Knewitz told GenomeWeb News last week that existing research deals were still under way, but could not comment on the future of the division's budget for such alliances.


Knewitz also said that "not many" of the 300 positions eliminated were in genomics research. "The majority of the genomics work is being done in La Jolla [California] and in Pennsylvania."


The lay-offs are in the company's Raritan, NJ office.


Laid-off employees will be able to apply for 100 new positions in the Spring House, Pa., office.


Companies GenomeWeb News spoke to who have collaborated with J&JPRD recently said they were not affected by the lay-offs.


"J&J is still one of our greatest partners. We're still very gung-ho here," said Jill Fujisaki, vice president scientific alliances of Entelos, which recently expanded a hematology research collaboration with the company.


Another company, GeneGo, renewed its database license to J&JPRD two weeks ago. GeneGo said the deal was for 12 months and represents the third year of that relationship.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.